Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30–40% response rate, many fall into the range of 10–20%, with delivery across the blood brain barrier...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Neurosci
Main Authors: Tivnan, Amanda, Zakaria, Zaitun, O'Leary, Caitrín, Kögel, Donat, Pokorny, Jenny L., Sarkaria, Jann N., Prehn, Jochen H. M.
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2015
Teme:
Pharmacology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468867/
https://ncbi.nlm.nih.gov/pubmed/26136652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnins.2015.00218
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki